A randomized phase III study compared capecitabine versus either lapatinib or pyrotinib in patients with HER2-positive breast cancer or metastatic breast cancer who previously received trastuzumab, taxanes, and/or anthracyclines. The gene discussed is ERBB2; the disease is breast cancer.